Australian survivors won the right to have the class action suit (against the drug’s manufacturer and distributor) heard in Australia, defeating a challenge by Grünenthal to have the case heard in Germany. This was significant because Lynette Rowe didn’t have to travel to Germany and it was also important because Germany had a complete ban on claims over 30 years old.